|Bid||1.8900 x 2200|
|Ask||1.9000 x 3100|
|Day's Range||1.8600 - 1.9900|
|52 Week Range||1.4900 - 5.2900|
|Beta (5Y Monthly)||1.18|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Recro Pharma (REPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 866 13F filings submitted by hedge funds and prominent investors. These filings show these funds’ portfolio positions as of March 31st, 2020. […]
Recro Pharma, Inc. ( NASDAQ:REPH ) investors will be delighted, with the company turning in some strong numbers with...